Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Methylphenidate for Asthenia in Advanced Cancer
NCT01773837Phase 3Terminated
- Sponsor
- Universidad de Navarra
- Start
- Jan 2012
- Primary completion
- Feb 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in cancer-related fatigue (CRF) comparing Methylphenidate with Placebo (2 arms). Primary endpoint: Intensity of asthenia assessed with the verbal numeric scale (VNS) included on the Edmonton Symptom Assessment System (ESAS) at Day 6. Started Jan 2012; status: terminated.
02
Drugs
methylphenidate
03
Conditions
cancer-related fatigue (CRF)
Beyond the preview
Go deeper on NCT01773837.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01773837.